BOLOGNA BOLOGNA, ROYAL HOTEL CARLTON. Bologna, Royal Hotel Carlton May 9-11, 2016 PROGRAM

Transcription

1 PROGRAM President: Pier Luigi Zinzani Co-President: Michele Cavo Honorary President: Sante Tura Bologna, Royal Hotel Carlton May 9-11, 2016 BOLOGNA BOLOGNA, ROYAL HOTEL CARLTON

2 Under the Auspices of UNIVERSITÀ DEGLI STUDI DI BOLOGNA REGIONE EMILIA-ROMAGNA AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA AIL ASSOCIAZIONE ITALIANA CONTRO LE LEUCEMIE - LINFOMI E MIELOMA SEZIONE DI BOLOGNA SIE - SOCIETÀ ITALIANA DI EMATOLOGIA

3 Faculty Sergio Amadori Roma, Italy Michele Baccarani Bologna, Italy Giovanni Barosi Pavia, Italy Peter Borchmann Cologne, Germany Tim H. Brummendorf Aachen, Germany Pier Luigi Canonico Novara, Italy Fausto Castagnetti Bologna, Italy Michele Cavo Bologna, Italy Francisco Cervantes Barcelona, Spain Bruce D. Cheson Washington, USA Paolo Corradini Milano, Italy Steven E. Coutre Stanford, USA Antonio Cuneo Ferrara, Italy Sven de Vos Los Angeles, USA Hartmut Dohner Ulm, Germany Martin Dreyling München, Germany Robin Foà Roma, Italy Nathan H. Fowler Houston, USA Armando Genazzani Novara, Italy Marco Gobbi Genova, Italy Hans C. Hasselbalch Copenhagen, Denmark Peter Hillmen Leeds, United Kingdom Brian Huntly Cambridge, United Kingdom Ilaria Iacobucci Memphis, USA Carl H. June Philadelphia, USA Hagop Kantarjian Houston, USA Michael G. Kauffman Newton, USA Arne Kolstad Oslo, Norway Shaji Kumar Rochester, USA Steven LeGouill Nantes, France Sagar Lonial Nantes, France Maurizio Martelli Roma, Italy Giovanni Martinelli Bologna, Italy Anthony Mato Philadelphia, USA Ruben A. Mesa Scottsdale, USA Philippe Moreau Nantes, France Frank Morschhauser Lille, France Alison J. Moskowitz New York, USA Owen A. O Connor New York, USA Susan M. O Brien Irvine, USA Michinori Ogura Gifu, Japan Antonio Palumbo Torino, Italy Fabrizio Pane Napoli, Italy Francesco Passamonti Varese, Italy Malte Peters Basel, Switzerland Ruth Pettengell London, United Kingdom Antonello Pinto Napoli, Italy Pierluigi Porcu Columbus, USA Vincent Ribrag Villejuif, France Paul G. Richardson Boston, USA Gianantonio Rosti Bologna, Italy Simon Rule Plymouth, United Kingdom Giuseppe Saglio Torino, Italy Stephen Schuster Philadelphia, USA Laurie H. Sehn Vancouver, Canada Michele Spina Aviano - PN, Italy Anastasios Stathis Bellinzona, Switzerland Eytan M. Stein New York, USA Richard M. Stone Boston, USA Aron Thall San Diego, USA Max S. Topp Würzburg, Germany Alessandro M. Vannucchi Firenze, Italy Umberto Vitolo Torino, Italy Thomas E. Witzig Rochester, USA Anas Younes New York, USA Pier Luigi Zinzani Bologna, Italy 1

4 Monday, May 9, a.m. Welcome and Introduction Three recent impressive stories Chairman: F. Pane 9.15 a.m. Brentuximab Vedotin in lymphomas - A. Younes 9.45 a.m. Blinatumumab in ALL - M.S. Topp a.m. CAR T-cells - C.H. June a.m. Coffee Break Session I: Classical Ph1-neg myeloproliferative neoplasms Chairmen: F. Passamonti, A.M. Vannucchi a.m. Status of the art of treatment - R.A. Mesa a.m. Ruxolitinib in myelofibrosis - F. Passamonti a.m. Ruxolitinib in polycitemia vera - A.M. Vannucchi a.m. New JAK2 inhibitors in MPNs and combination therapy - F. Cervantes p.m. Interferons in MPNs - H.C. Hasselbalch p.m. Newer drugs for myelofibrosis - G. Barosi p.m. Lunch 2

5 Session II: Hodgkin s lymphoma Chairmen: P. Borchmann, P.L. Zinzani 1.45 p.m. Status of the art of treatment - P. Borchmann 2.10 p.m. Nivolumab - A. Younes 2.25 p.m. Pembrolizumab - S. Schuster 2.40 p.m. Bendamustine - A.J. Moskowitz 2.55 p.m. New Combo-steps - A. Younes Session III: Chronic myeloid leukemia Chairmen: M. Gobbi, G. Rosti 3.30 p.m. Status of the art of treatment - M. Baccarani 3.55 p.m. Nilotinib-based treatments and ABL001 - F. Castagnetti 4.15 p.m. Dasatinib and combination - G. Saglio 4.30 p.m. Bosutinib - T.H. Brummendorf 4.45 p.m. Ponatinib - G. Rosti 3

6 Tuesday, May 10, 2016 Two transversal on lymphomas drugs Chairman: P. Corradini 8.30 a.m. Bendamustine - B.D. Cheson 9.00 a.m. Lenalidomide - T.E. Witzig Session IV: Non-Hodgkin s lymphoma (I) Chairmen: B.D. Cheson, A. Pinto 9.15 a.m. Status of the art of treatment - B.D. Cheson 9.40 a.m. Obinutuzumab - L.H. Sehn 9.55 a.m. Ublituximab - N.H. Fowler a.m. MOR208 - P.L. Zinzani a.m. anti-4-1bb - A. Thall a.m. Polatuzumab - F. Morschhauser a.m. Mogamulizumab - M. Ogura a.m. 177Lu-HH1 (Betalutin) - A. Kolstad a.m. CC V. Ribrag a.m. EDO-S101 - O.A. O Connor p.m. IMGN529 - A. Stathis p.m. Selinexor - M.G. Kauffman p.m. Pixantrone - R. Pettengell 1.00 p.m. Lunch 4

7 Session V: Non-Hodgkin s lymphoma (II) Chairmen: M. Martelli, U. Vitolo 2.00 p.m. Venetoclax - S. Rule 2.15 p.m. Idelalisib - S. de Vos 2.30 p.m. Ibrutinib - S. Rule 2.45 p.m. TGR O.A. O Connor 3.00 p.m. Copanlisib - M. Dreyling 3.15 p.m. Duvelisib - N.H. Fowler 3.30 p.m. Acalabrutinib - S. LeGouill 3.45 p.m. Tazemetostat - V. Ribrag Session VI: Chronic Lymphocitic Leukemia Chairmen: A. Cuneo, R. Foà 4.15 p.m. Status of the art of management - S.M. O Brien 4.45 p.m. Ibrutinib - P. Hillmen 5.00 p.m. Idelalisib - S.E. Coutre 5.15 p.m. Venetoclax - P. Hillmen 5.30 p.m. Acalabrutinib - S.M. O Brien 5.45 p.m. Duvelisib - P. Porcu 6.00 p.m. TGR-1202 and Ublituximab - A. Mato 5

8 Wednesday, May 11, 2016 Session VII: Multiple myeloma Chairmen: M. Cavo, S. Lonial 8.30 a.m. Status of the art of treatment - A. Palumbo 8.55 a.m. Modelling of disease evolution: what have we learned and how can we drive future treatment strategies? - P.G. Richardson 9.10 a.m. Immune checkpoint inhibitors and immune-based therapies - P.G. Richardson 9.25 a.m. New insights into optimal use of PIs and IMiDs based on sensitizing targets and biomarkers - P. Moreau 9.40 a.m. Histone deacetilase and kinase inhibitors - S. Lonial 9.55 a.m. Monoclonal antibodies and their integration into the modern therapeutic algorithms - M. Cavo a.m. Is personalized therapy ready for primetime? - S.K. Kumar Other two interesting issues Chairmen: A. Genazzani, P.L. Zinzani a.m. Rituximab biosimilars - P.L. Canonico, M. Peters a.m. The role of liposomal doxorubicin in DLBCL lymphomas - M. Spina Session VIII: Acute leukemia Chairmen: S. Amadori, G. Martinelli a.m. Status of the art of treatment - H. Dohner a.m. Targeting BET in acute myeloid leukemia - B. Huntly 6

9 12.10 p.m. IDH2 inhibitors in acute myeloid leukemia - E.M. Stein p.m. FLT3 inhibitors in acute myeloid leukemia - R.M. Stone p.m. Inotuzumab ozogamicin in acute lymphoblastic leukemia - H. Kantarjian p.m. BCR-ABL like in acute lymphoblastic leukemia - I. Iacobucci p.m. The role of RO in acute myeloid leukemia - G. Martinelli 1.30 p.m. Conclusions and Arrivederci 7

10 GENERAL INFORMATION MEETING VENUE Royal Hotel Carlton Via Montebello, Bologna, Italy Phone Fax OFFICIAL LANGUAGE English REGISTRATION FEE Euro 400,00 (Italian VAT included) The registration fee includes: Conference kit, partecipation in the scientific sessions, attendance certificate, coffee breaks, lunch, slides of the meeting. BADGE All registered participants, speakers and exhibitors will be given a badge which they must wear to be admitted to the scientific sessions. ATTENDANCE CERTIFICATE A certificate will be given to all participants at the end of the meeting. ITALIAN CME CREDITS A request for Italian CME credits have been made as follows: - Provider Studio ER Congressi SRL: ID No. 10 CME credits for physicians (disciplines: Allergology and Clinical Immunology, Dermatology and Venereology, Hematology, Oncology, Pathological Anatomy, Clinical Biochemistry, Clinical Pathology), biologists and chemists. - Educational objective: guidelines-protocols-procedures. EUROPEAN CME CREDITS The program of the New Drugs in Hematology has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 20 CME credits for Physicians, Biologists and Chemists. To request credits, please fill out the form and return it to the registration desk at the end of the meeting. We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: even on site. CHANGES Parts of the program may be changed without notice. 8

11 ACKNOWLEDGEMENTS TM

12 Scientific Secretariat Pier Luigi Zinzani Istituto di Ematologia Lorenzo e Ariosto Seràgnoli Via Massarenti, Bologna, Italy Phone Fax pierluigi.zinzani@unibo.it Organizing Secretariat Studio E.R. Congressi Via Marconi, Bologna, Italy Phone Fax ercongressi@ercongressi.it struchel.com